Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Hodgkin lymphoma: Current and future therapeutic strategies].
Turpin A, Michot JM, Kempf E, Mazeron R, Dartigues P, Terroir M, Boros A, Bonnetier S, Castilla-Llorente C, Coman T, Danu A, Ghez D, Pilorge S, Arfi-Rouche J, Dercle L, Soria JC, Carde P, Ribrag V, Fermé C, Lazarovici J. Turpin A, et al. Among authors: lazarovici j. Bull Cancer. 2018 Jan;105(1):81-98. doi: 10.1016/j.bulcan.2017.11.008. Epub 2017 Dec 27. Bull Cancer. 2018. PMID: 29289336 Review. French.
Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Michot JM, Mazeron R, Danu A, Lazarovici J, Ghez D, Antosikova A, Willekens C, Chamseddine AN, Minard V, Dartigues P, Bosq J, Carde P, Koscielny S, De Botton S, Ferme C, Girinsky T, Ribrag V. Michot JM, et al. Among authors: lazarovici j. Eur J Cancer. 2015 Nov;51(16):2386-95. doi: 10.1016/j.ejca.2015.07.009. Epub 2015 Aug 5. Eur J Cancer. 2015. PMID: 26254810
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
Lazarovici J, Dartigues P, Brice P, Obéric L, Gaillard I, Hunault-Berger M, Broussais-Guillaumot F, Gyan E, Bologna S, Nicolas-Virelizier E, Touati M, Casasnovas O, Delarue R, Orsini-Piocelle F, Stamatoullas A, Gabarre J, Fornecker LM, Gastinne T, Peyrade F, Roland V, Bachy E, André M, Mounier N, Fermé C. Lazarovici J, et al. Haematologica. 2015 Dec;100(12):1579-86. doi: 10.3324/haematol.2015.133025. Epub 2015 Oct 1. Haematologica. 2015. PMID: 26430172 Free PMC article.
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Dupuis J, Morschhauser F, Ghesquières H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, Le Bras F, Bachy E, Hivert B, Nicolas-Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B. Dupuis J, et al. Among authors: lazarovici j. Lancet Haematol. 2015 Apr;2(4):e160-5. doi: 10.1016/S2352-3026(15)00023-X. Epub 2015 Mar 17. Lancet Haematol. 2015. PMID: 26687958 Clinical Trial.
[Consortium for detection and management of lung damage induced by bleomycin].
Biya J, Stoclin A, Dury S, Le Pavec J, Mir O, Lazarovici J, Fermé C, Annereau M, Ekpe K, Massard C, Michot JM. Biya J, et al. Among authors: lazarovici j. Bull Cancer. 2016 Jul-Aug;103(7-8):651-61. doi: 10.1016/j.bulcan.2016.04.005. Epub 2016 May 27. Bull Cancer. 2016. PMID: 27241272 Review. French.
Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.
Annereau M, Willekens C, El Halabi L, Chahine C, Saada V, Auger N, Danu A, Bermudez E, Lazarovici J, Ghez D, Leary A, Pistilli B, Lemare F, Solary E, de Botton S, Desmaris RP, Micol JB. Annereau M, et al. Among authors: lazarovici j. Leuk Res. 2017 Apr;55:58-64. doi: 10.1016/j.leukres.2017.01.024. Epub 2017 Jan 20. Leuk Res. 2017. PMID: 28131982
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F. Herbaux C, et al. Among authors: lazarovici j. Blood. 2017 May 4;129(18):2471-2478. doi: 10.1182/blood-2016-11-749556. Epub 2017 Mar 7. Blood. 2017. PMID: 28270452 Free article. Clinical Trial.
Immune-related bone marrow failure following anti-PD1 therapy.
Michot JM, Vargaftig J, Leduc C, Quere G, Burroni B, Lazarovici J, Champiat S, Ribrag V, Lambotte O. Michot JM, et al. Among authors: lazarovici j. Eur J Cancer. 2017 Jul;80:1-4. doi: 10.1016/j.ejca.2017.04.004. Epub 2017 May 17. Eur J Cancer. 2017. PMID: 28527392 No abstract available.
18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor.
Dercle L, Seban RD, Lazarovici J, Schwartz LH, Houot R, Ammari S, Danu A, Edeline V, Marabelle A, Ribrag V, Michot JM. Dercle L, et al. Among authors: lazarovici j. J Nucl Med. 2018 Jan;59(1):15-24. doi: 10.2967/jnumed.117.193011. Epub 2017 Jun 8. J Nucl Med. 2018. PMID: 28596157 Free article.
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Michot JM, Benajiba L, Faivre L, Baldini C, Haddag L, Bonnet C, Massard C, Bigot F, Bigenwald C, Verret B, Thomas ZAP, Varga A, Gazzah A, Hollebecque A, Ghez D, Lazarovici J, Balheda R, Jeanson A, Postel-Vinay S, Danu A, Soria JC, Paoletti X, Ribrag V. Michot JM, et al. Among authors: lazarovici j. Invest New Drugs. 2018 Feb;36(1):62-74. doi: 10.1007/s10637-017-0480-x. Epub 2017 Jun 9. Invest New Drugs. 2018. PMID: 28597151 Clinical Trial.
61 results